Quick Answer
Theravance Biopharma, Inc. reported R&D Expense of $37.41 million for fiscal year 2025.
Theravance Biopharma, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $37.41M | -0.6% |
| 2024 | $37.64M | -7.3% |
| 2023 | $40.62M | -35.9% |
| 2022 | $63.39M | -67.3% |
| 2021 | $193.66M | -25.8% |
| 2020 | $260.95M | +19.0% |
| 2019 | $219.25M | +8.9% |
| 2018 | $201.35M | +15.8% |
| 2017 | $173.89M | +22.7% |
| 2016 | $141.71M | +9.7% |
| 2015 | $129.16M | -23.4% |
| 2014 | $168.52M | +39.8% |
| 2013 | $120.58M | +5.8% |
| 2012 | $114.00M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $8.11M | -12.5% | -22.7% |
| June 30, 2025 | $10.49M | +5.4% | -8.4% |
| March 31, 2025 | $11.45M | +27.7% | +23.6% |
| September 30, 2024 | $9.27M | +11.5% | -6.9% |
| June 30, 2024 | $9.95M | +5.6% | +11.0% |
| March 31, 2024 | $8.97M | -38.5% | +7.9% |
| September 30, 2023 | $8.31M | -15.8% | -11.8% |
| June 30, 2023 | $9.43M | -36.8% | -35.3% |
- Theravance Biopharma, Inc. showed a decrease of -0.6% in R&D Expense compared to the prior fiscal year.
- Over the 2012–2025 period, Theravance Biopharma, Inc.’s r&d expense has declined by 67.2% (from $114.00 million to $37.41 million).
- The most recent figure is from Theravance Biopharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: